Literature DB >> 26585536

Two decades of new drug development for central nervous system disorders.

Aaron S Kesselheim1, Thomas J Hwang2, Jessica M Franklin1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26585536     DOI： 10.1038/nrd4793

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  32 in total

1.  Derisking Psychiatric Drug Development: The NIMH's Fast Fail Program, A Novel Precompetitive Model.

Authors:  Margaret C Grabb; Alan J Cross; William Z Potter; James T McCracken
Journal:  J Clin Psychopharmacol       Date:  2016-10       Impact factor: 3.153

Review 2.  Clinical Pharmacokinetics and Pharmacodynamics of Drugs in the Central Nervous System.

Authors:  Nithya Srinivas; Kaitlyn Maffuid; Angela D M Kashuba
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

Review 3.  Compartmentalized Devices as Tools for Investigation of Human Brain Network Dynamics.

Authors:  Joseph A Fantuzzo; Ronald P Hart; Jeffrey D Zahn; Zhiping P Pang
Journal:  Dev Dyn       Date:  2018-09-12       Impact factor: 3.780

4.  Enantioselective Syntheses of Yohimbine Alkaloids: Proving Grounds for New Catalytic Transformations.

Authors:  Eric R Miller; Karl A Scheidt
Journal:  Synthesis (Stuttg)       Date:  2021-11-02       Impact factor: 2.969

5.  Development of a high-throughput arrayed neural circuitry platform using human induced neurons for drug screening applications.

Authors:  Joseph A Fantuzzo; Denise A Robles; Vincent R Mirabella; Ronald P Hart; Zhiping P Pang; Jeffrey D Zahn
Journal:  Lab Chip       Date:  2020-03-17       Impact factor: 6.799

6.  The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development.

Authors:  Andrew D Krystal; Diego A Pizzagalli; Sanjay J Mathew; Gerard Sanacora; Richard Keefe; Allen Song; Joseph Calabrese; Andrew Goddard; Wayne Goodman; Sarah H Lisanby; Moria Smoski; Richard Weiner; Dan Iosifescu; John Nurnberger; Steven Szabo; James Murrough; Anantha Shekhar; William Potter
Journal:  Nat Rev Drug Discov       Date:  2018-12-28       Impact factor: 84.694

Review 7.  New Frontiers in Parkinson's Disease: From Genetics to the Clinic.

Authors:  Lamya S Shihabuddin; Patrik Brundin; J Timothy Greenamyre; Diane Stephenson; S Pablo Sardi
Journal:  J Neurosci       Date:  2018-10-31       Impact factor: 6.167

8.  A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia.

Authors:  Andrew D Krystal; Diego A Pizzagalli; Moria Smoski; Sanjay J Mathew; John Nurnberger; Sarah H Lisanby; Dan Iosifescu; James W Murrough; Hongqiu Yang; Richard D Weiner; Joseph R Calabrese; Gerard Sanacora; Gretchen Hermes; Richard S E Keefe; Allen Song; Wayne Goodman; Steven T Szabo; Alexis E Whitton; Keming Gao; William Z Potter
Journal:  Nat Med       Date:  2020-03-30       Impact factor: 53.440

9.  The novel vasopressin receptor (V1aR) antagonist SRX246 reduces anxiety in an experimental model in humans: a randomized proof-of-concept study.

Authors:  Tiffany R Lago; Michael J Brownstein; Emily Page; Emily Beydler; Adrienne Manbeck; Alexis Beale; Camille Roberts; Nicholas Balderston; Eve Damiano; Suzanne L Pineles; Neal Simon; Monique Ernst; Christian Grillon
Journal:  Psychopharmacology (Berl)       Date:  2021-05-10       Impact factor: 4.530

Review 10.  Microphysiological systems to study tumor-stroma interactions in brain cancer.

Authors:  Edward R Neves; Brendan A C Harley; Sara Pedron
Journal:  Brain Res Bull       Date:  2021-06-21       Impact factor: 3.715
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.